Glucophage Generics Coming Soon, Bristol Says; Exclusivity Bill Clears Senate
Executive Summary
Bristol-Myers Squibb expects the pediatric exclusivity reauthorization bill to be signed into law by the end of the month
You may also be interested in...
Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgments
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgments
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
House Generic Drug Debate Will Likely Begin With Rep. Thune Bill
Consideration of generic drug legislation in the House will likely begin with a bill introduced by Rep. John Thune (R-S.D.)